A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.
Teva Pharmaceutical Industries has named Carlo De Notaristefani as president and CEO of global operations and Aharon "Arik" Yaari as EVP community and institutional affairs, the Israeli drug maker said Thursday.
Following regulatory approval by the Food and Drug Administration's Center for Biologics Evaluation and Research, GlaxoSmithKline confirmed it has begun shipping the first lots of its 2012-2013 seasonal influenza vaccines to healthcare providers and Centers for Disease Control and Prevention distribution centers.
As many as 47 million women will be gaining greater control over their health care and access to eight new prevention-related healthcare services without paying more out of their own pocket beginning Aug. 1, Health and Human Services secretary Kathleen Sebelius announced Tuesday.
A drug made by Bristol-Myers Squibb and AstraZeneca improved several measures of blood-sugar control in Type 2 diabetes patients at high risk of cardiovascular disease, according to results of a late-stage clinical trial announced Monday.
In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.
The Senate Committee on Commerce, Science and Transportation on Wednesday released a staff report on the investigation into the gray market for pharmaceuticals — what the committee defined as "shady operators who make enormous profits by buying hard-to-find drugs and reselling them at huge markups" — specifically naming pharmacies as a primary culprit.
An experimental drug under development by Pfizer and a unit of Johnson & Johnson does not appear effective in Alzheimer's disease patients who carry a certain genotype, according to results of a late-stage clinical trial announced by Pfizer on Tuesday.
The Centers for Medicare and Medicaid Services on Monday hosted a public meeting to entertain a controversial payment adjustment — called "inherent reasonableness" — in reimbursing for non-mail-order diabetes supplies.